Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects

Completed · Phase 1

Conditions studied: Hyperglycemia, Sepsis

In brief

This is a clinical study of a drug named dopamine and how it affects our bodies ability to make and secrete insulin. Insulin is a hormone made in the pancreas that helps our body regulate sugar levels. We think that this drug decreases the amount of insulin our body makes and causes our sugar levels to be high. When you are critically ill there can be many adverse effects if you have sugar levels that are too high.

Key facts

Study ID

NCT02053935

Run by

Albert Einstein College of Medicine

People needed

15

Starts

2013-12-01

Expected to finish

2016-01-01

Last updated by the study team

2016-08-09

Who can join

Age: 18 and older, up to 35. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects
• Age 18-35 years
• Hemoglobin >12 g/dl
• Euthyroid or on a stable dose of synthroid
• Normal EKG, hemoglobin AIC, kidney and liver function

You may not qualify if…

• Prior history of dopamine infusion
• Past medical history of diabetes, hypertension, myocardial infarction, vaso-occlusive disease or arrhythmias
• Chronic steroid therapy, oral contraceptive pills, monoamine oxidase inhibitors (MAO-I), anticonvulsants (phenytoin)
• Pregnant women because dopamine is pregnancy category C
• Clinical signs of polycystic ovarian syndrome
• Past medical history of Cushing's disease or pheochromocytoma
• Sulfa drug allergy
• Use of any medications or illness determined by the investigators that may affect insulin secretion or insulin sensitivity.

Where it is running

• Montefiore Medical Center of Albert Einstein College of Medicine — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.